Nicotinamide and glaucoma: promising retinal signals, real safety limits

A retinal signal is not established vision protection

Nicotinamide has produced interesting signals in small glaucoma trials, but that is different from showing that a supplement preserves sight over years. The studies examined specific retinal-function and visual-field measures alongside existing glaucoma care. ^{[1] [2]} They do not justify replacing pressure-lowering treatment or selecting an unrelated NAD product for eye protection. The exact ingredient matters: nicotinamide is not the same intervention as nicotinic acid, NR or NMN. This is also an area where safety changes the conclusion. A promising early signal should be read beside the professional position on high-dose nicotinamide, rather than promoted as a simple vitamin purchase. ^[3]

Start with why NAD-related ingredients are not interchangeable when a product name blurs the intervention.

The first crossover trial was an adjunct study

Hui and colleagues randomized fifty-seven people already being treated for glaucoma in a double-masked crossover trial. The nicotinamide phase used 1.5 g daily for six weeks and then 3 g daily for six weeks, followed by crossover without a washout. ^[1] These amounts describe supervised research and are not instructions for self-treatment. The design asked whether function changed during a short period, not whether the regimen prevented blindness. Keeping concurrent treatment visible also prevents a misleading story in which the supplement appears to have been tested as an alternative to usual care rather than as an investigational addition.

The endpoint needs its full name

In the Hui trial, a retinal electrophysiology response improved beyond the repeatability threshold in 23 percent during nicotinamide versus 9 percent during placebo. The photopic negative-response amplitude improved by 14.8 percent on nicotinamide, with a 95 percent confidence interval of 2.8 to 26.9 percent. ^[1] That is a specific physiological measurement. It is not a fourteen-percent restoration of eyesight. A retinal signal can help investigators detect a potentially useful effect before a long outcome study is feasible, while still requiring further work to show that the change means less damage or better preserved everyday visual function.

A later study addressed normal-tension glaucoma

A separate crossover trial enrolled fifty-three participants with normal-tension glaucoma who continued pressure-lowering therapy. Each twelve-week phase escalated nicotinamide from 1 g to 2 g daily after six weeks, again without a washout. The reported photopic negative-response change was 3.121 versus 0.996 microvolts for nicotinamide and placebo; the trial did not establish a corresponding significant improvement in visual-field indices. ^[2] The preparation and population remain specific. This should not become a claim that any NAD booster improves vision, or that a laboratory change guarantees protection against a person’s future pattern of glaucoma progression.

Crossover designs have useful limits

A crossover experiment allows participants to receive both treatments and can make a small study more informative. It also raises questions about period effects, residual effects and what happens when there is no washout. Those questions do not erase a result, but they affect how confidently the effect can be generalized. Repeated testing can have its own variability, and a short functional response does not necessarily describe the longer disease course. The practical interpretation is to treat these as signals deserving confirmation. A larger, longer trial should establish whether the intervention produces an outcome patients value, not merely repeat the most attractive short-term percentage. The practical issue is whether a short signal predicts preserved ability to see over time. A stronger electrophysiology response is not automatically the same as slower structural damage, and the experiment needs follow-up designed to distinguish those possibilities before a treatment claim becomes dependable.

The liver concern changes the shopping decision

The American Glaucoma Society and American Academy of Ophthalmology issued a position statement after reports of liver injury in this research area. They advise against high-dose nicotinamide at 3 g daily or more outside closely monitored clinical trials and call for physician collaboration and liver-function monitoring when lower amounts are being considered. ^[3] This is not a recommendation to choose an amount just below that threshold. The point is that the clinical decision needs oversight and uncertainty remains. A familiar vitamin name does not turn a research regimen into a routine eye-health supplement or remove the possibility of serious harm.

What should count as a stronger result

A more decisive trial would examine sustained progression of structural or visual-field damage over an adequate interval, alongside adverse events and adherence. It should distinguish any short-term functional improvement from actual neuroprotection. It would also need a clear account of who was enrolled and what usual care continued. Those requirements explain why a promising early paper can coexist with a cautious clinical position. Researchers may reasonably investigate the mechanism while clinicians remain unwilling to recommend broad self-treatment. There is no contradiction: the question is whether the evidence has crossed the threshold for the specific decision being made.

Where NAD-product comparisons fit

For someone considering an NAD-related product, the glaucoma studies are a reason to be precise rather than a reason to add more supplements. Do not infer that an NR capsule, NMN powder or direct NAD preparation reproduces nicotinamide findings. Discuss any contemplated use with the eye-care team and primary clinician, keeping established glaucoma treatment and follow-up intact. Product labels and purchase terms become relevant only after that clinical discussion. The useful conclusion is measured: nicotinamide has shown retinal-function signals in small adjunct trials, while long-term vision benefit, optimal use and a manageable safety profile remain questions that an ordinary retail purchase cannot answer.

For an example of a different NAD-related ingredient, read our Life Extension NAD+ Cell Regenerator review; this is not a glaucoma-treatment recommendation.